Product Highlight - Spikevax LP.8.1

PROTECT YOUR PATIENTS FROM THE EVOLVING COVID-19 THREAT

• Spikevax LP.8.1 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older. ¹

• Tolerable safety profile: Most common side effects include injection site pain, fatigue, headache, myalgia, arthralgia and lymphadenopathy. ¹

• Simple administration: Pre-filled syringe for intramuscular injection. ¹

Reference: 1. Spikevax LP.8.1 dispersion for injection in pre-filled syringe COVID-19 mRNA Vaccine 50 micrograms/dose 0.5ml Prescribing Information. December 2025.